NCT00929175

Brief Summary

Obstructive sleep apnea syndrome (OSAS) has been linked to resistant hypertension, but the effect of treatment of OSAS on the resistant hypertension have no been established. In a double-blind randomized clinical trial patients with resistant hypertension with at least moderate sleep apnea will be randomized to receive therapeutic CPAP or Placebo CPAP for eight weeks in an ambulatory set. The investigators want to determine any difference on hypertension control between the 2 management strategies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at below P25 for phase_4 hypertension

Timeline
Completed

Started Feb 2008

Longer than P75 for phase_4 hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2008

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 9, 2009

Completed
17 days until next milestone

First Posted

Study publicly available on registry

June 26, 2009

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
Last Updated

February 25, 2014

Status Verified

April 1, 2013

Enrollment Period

5.2 years

First QC Date

June 9, 2009

Last Update Submit

February 24, 2014

Conditions

Keywords

HypertensionResistant HypertensionSleep apnea syndromeTreatment

Outcome Measures

Primary Outcomes (1)

  • Blood pressure evaluated with ambulatory 24-hour blood pressure monitoring

    8 weeks after treatment

Secondary Outcomes (1)

  • aldosterone, renin, activated protein C

    8 weeks

Study Arms (2)

active CPAP

ACTIVE COMPARATOR

auto-PAP with therapeutic pressure

Device: active CPAP

sham-CPAP

SHAM COMPARATOR

auto-PAP with pressure less than 1cm H2O

Device: sham-CPAP

Interventions

auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients

active CPAP
sham-CPAPDEVICE

The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.

sham-CPAP

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of resistant hypertension
  • Apnea/hypopnea index \> 15

You may not qualify if:

  • Cardiac surgery on last 3 months
  • Serious arrhythmias
  • Insulin dependent diabetes
  • Debilitating neurological disease
  • severe COPD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90035003, Brazil

Location

Related Publications (1)

  • de Oliveira AC, Martinez D, Massierer D, Gus M, Goncalves SC, Ghizzoni F, Steinhorst AM, Moreira LB, Fuchs SC, Fuchs FD. The antihypertensive effect of positive airway pressure on resistant hypertension of patients with obstructive sleep apnea: a randomized, double-blind, clinical trial. Am J Respir Crit Care Med. 2014 Aug 1;190(3):345-7. doi: 10.1164/rccm.201403-0479LE. No abstract available.

MeSH Terms

Conditions

HypertensionSleep Apnea Syndromes

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Flavio D Fuchs

    Hospital de Clínicas de Porto Alegre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2009

First Posted

June 26, 2009

Study Start

February 1, 2008

Primary Completion

April 1, 2013

Study Completion

April 1, 2013

Last Updated

February 25, 2014

Record last verified: 2013-04

Locations